Adage Capital Partners’s Vaxcyte PCVX Stock Holding History

Adage Capital Partners’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$51.2M	Buy	880,000 +530,000	+151%	+$28.8M	0.07%	274
2026 Q1	$20.3M	Sell	350,000 -1,375,000	-80%	-$74.6M	0.03%	462
2025 Q4	$79.6M	Buy	1,725,000 +1,392,000	+418%	+$62.3M	0.12%	166
2025 Q3	$12M	Buy	+333,000	New	+$11M	0.02%	598
2024 Q3	–	Sell	-85,088	Closed	-$6.42M	–	922
2024 Q2	$6.42M	Hold	85,088	–	–	0.01%	682
2024 Q1	$5.81M	Sell	85,088 -65,000	-43%	-$4.5M	0.01%	681
2023 Q4	$9.43M	Buy	150,088 +18,000	+14%	+$935K	0.02%	603
2023 Q3	$6.73M	Buy	132,088 +72,000	+120%	+$3.55M	0.02%	629
2023 Q2	$3M	Sell	60,088 -374,912	-86%	-$17.8M	0.01%	717
2023 Q1	$16.3M	Sell	435,000 -360,000	-45%	-$15.3M	0.04%	487
2022 Q4	$38.1M	Buy	795,000 +695,000	+695%	+$27.3M	0.09%	257
2022 Q3	$2.4M	Buy	100,000 +47,100	+89%	+$1.19M	0.01%	843
2022 Q2	$1.15M	Buy	+52,900	New	+$1.22M	﹤0.01%	916

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Adage Capital Partners's PCVX Position: Q2 2026 in Review

Adage Capital Partners increased its Vaxcyte (PCVX) stake by 151% in Q2 2026, buying an estimated $28.8M and bringing the position to 880,000 shares worth $51.2M. The position accounts for 0.07% of the portfolio, ranked #274.

Adage Capital Partners first reported a position in PCVX in Q2 2022 and has held it in 13 quarters since. The position peaked at $79.6M in Q4 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Adage Capital Partners held 880,000 shares of Vaxcyte worth $51.2M as of Q2 2026.
Adage Capital Partners bought 530,000 Vaxcyte shares in Q2 2026, an estimated $28.8M.
Vaxcyte made up 0.07% of Adage Capital Partners's portfolio in Q2 2026, its #274 holding.
Adage Capital Partners first reported a position in Vaxcyte in Q2 2022 and has held it in 13 quarters since.
Adage Capital Partners's Vaxcyte position peaked at $79.6M in Q4 2025.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.